Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pediatric Asthma Controller Trial (PACT)

This study has been completed.
Childhood Asthma Research and Education Network
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: January 3, 2006
Last updated: July 11, 2016
Last verified: January 2006
To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.

Condition Intervention Phase
Lung Diseases
Drug: inhaled corticosteroid
Drug: long-acting beta2-agonist
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Primary Purpose: Treatment

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: August 2002
Study Completion Date: September 2004
  Show Detailed Description


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Asthmatic children from birth to 18 years. Emphasis is placed on infants and young children through 5 years of age.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00272506

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Childhood Asthma Research and Education Network
OverallOfficial: Vernon Chinchilli Milton S. Hershey Medical Center
OverallOfficial: Robert Lemanske University of Wisconsin, Madison
OverallOfficial: Fernando Martinez University of Arizona
OverallOfficial: Robert Strunk Washington University School of Medicine
OverallOfficial: Stanley Szefler National Jewish Health
OverallOfficial: Robert Zeiger University of California, San Diego
  More Information Identifier: NCT00272506     History of Changes
Other Study ID Numbers: 351 
Study First Received: January 3, 2006
Last Updated: July 11, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Lung Diseases
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on October 26, 2016